Loading...
| A03265 | Pages: NA | Dec 2021 | 4725 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Metacycline Market
Request Now !Metacycline is a broad spectrum semisynthetic antibiotic that belongs to tetracycline drug class. Esarondil, physiomycine, lysocline, and rotilen are some of the brand names of the antibiotic. Metacycline inhibits protein synthesis and hence cell growth by preventing the binding of aminoacyl transfer RNA to the m-RNA-ribosome complex in the ribosome 30S subunit. The antibiotic is administered in the form of oral tablets.
The wide spectrum of antimicrobial action with the use of metacyclin makes it an active component against gram-positive and gram-negative bacteria. The increase in the incidence of diseases such as rickettsiae, pneumonia, sinusitis, trench fever, and typhus increases the demand for metacycline, which in turn boosts the market growth. Nevertheless, the adverse effects associated with the use of metacycline such as hepatotoxicity, diarrhea, nausea, enterocolitis, and diarrhea hamper the market growth. In addition, the rise in the number of antibiotic resistant organisms and availability of substitutes such as miciclin, monatrex, and muvito also limit the growth of the market.
The global metacycline market is segmented based on application and geography. Based on therapeutics, it is classified into chronic bronchitis, rickettsial infections, pneumonia, trench fever, typhus, Q fever, sinusitis, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Merck, Boc Sciences, Manus Aktteva Biopharma LLP, Cayman Chemical, Hycultec GmbH, Abcam plc, Santa Cruz Biotechnology, Inc., Hlzel Biotech, Changzhou Pharmaceutical Factory, and The ND Pharma & Biotech Company are also provided in the report.
Key Benefits
CHAPTER 1INTRODUCTION
1.1.REPORT DESCRIPTION
1.2.KEY BENEFITS
1.3.KEY MARKET SEGMENTS
1.4.RESEARCH METHODOLOGY
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2EXECUTIVE SUMMARY
2.1.CXO PERSPECTIVE
CHAPTER 3MARKET OVERVIEW
3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.MARKET SHARE ANALYSIS, 2016
3.4.PORTER’S FIVE FORCES ANALYSIS
3.4.1.MARKET DYNAMICS
3.4.2.Drivers
3.4.3.Restraints
3.4.4.Opportunities
CHAPTER 4METACYCLINE MARKET, BY THERAPEUTICS
4.1.OVERVIEW
4.1.1.Market size and forecast
4.2.CHRONIC BRONCHITIS
4.2.1.Key market trends
4.2.2.Growth factors and opportunities
4.2.3.Market size and forecast
4.3.RICKETTSIAL INFECTIONS
4.3.1.Key market trends
4.3.2.Growth factors and opportunities
4.3.3.Market size and forecast
4.4.PNEUMONIA
4.4.1.Key market trends
4.4.2.Growth factors and opportunities
4.4.3.Market size and forecast
4.5.TRENCH FEVER
4.5.1.Key market trends
4.5.2.Growth factors and opportunities
4.5.3.Market size and forecast
4.6.TYPHUS
4.6.1.Key market trends
4.6.2.Growth factors and opportunities
4.6.3.Market size and forecast
4.7.Q FEVER
4.7.1.Key market trends
4.7.2.Growth factors and opportunities
4.7.3.Market size and forecast
4.8.SINUSITIS
4.8.1.Key market trends
4.8.2.Growth factors and opportunities
4.8.3.Market size and forecast
4.9.OTHERS
4.9.1.Key market trends
4.9.2.Growth factors and opportunities
4.9.3.Market size and forecast
CHAPTER 5METACYCLINE MARKET, BY GEOGRAPHY
5.1.OVERVIEW
5.2.NORTH AMERICA
5.2.1.Key market trends
5.2.2.Key growth factors and opportunities
5.2.3.Market size and forecast
5.2.3.1.U.S. market size and forecast
5.2.3.2.Canada market size and forecast
5.2.3.3.Mexico market size and forecast
5.2.4.North America Metacycline Market by Therapeutics
5.3.EUROPE
5.3.1.Key market trends
5.3.2.Key growth factors and opportunities
5.3.3.Market size and forecast
5.3.3.1.Germany market size and forecast
5.3.3.2.France market size and forecast
5.3.3.3.UK market size and forecast
5.3.3.4.Italy market size and forecast
5.3.3.5.Spain market size and forecast
5.3.3.6.Rest of Europe market size and forecast
5.3.4.Europe Metacycline Market by Therapeutics
5.4.ASIA-PACIFIC
5.4.1.Key market trends
5.4.2.Key growth factors and opportunities
5.4.3.Market size and forecast
5.4.3.1.Japan market size and forecast
5.4.3.2.China market size and forecast
5.4.3.3.Australia market size and forecast
5.4.3.4.India market size and forecast
5.4.3.5.South Korea market size and forecast
5.4.3.6.Taiwan market size and forecast
5.4.3.7.Rest of Asia-Pacific market size and forecast
5.4.4.Asia-Pacific Metacycline Market by Therapeutics
5.5.LAMEA
5.5.1.Key market trends
5.5.2.Key growth factors and opportunities
5.5.3.Market size and forecast
5.5.3.1.Brazil market size and forecast
5.5.3.2.Turkey market size and forecast
5.5.3.3.Saudi Arabia market size and forecast
5.5.3.4.South Africa market size and forecast
5.5.3.5.Rest of LAMEA market size and forecast
5.5.4.LAMEA Metacycline Market by Therapeutics
CHAPTER 6COMPANY PROFILES
6.1.MERCK
6.1.1.Operating business segments
6.1.2.Business performance
6.1.3.Key strategic moves and developments
6.2.BOC SCIENCES
6.2.1.Operating business segments
6.2.2.Business performance
6.2.3.Key strategic moves and developments
6.3.MANUS AKTTEVA BIOPHARMA LLP
6.3.1.Operating business segments
6.3.2.Business performance
6.3.3.Key strategic moves and developments
6.4.CAYMAN CHEMICAL
6.4.1.Operating business segments
6.4.2.Business performance
6.4.3.Key strategic moves and developments
6.5.HYCULTEC GMBH
6.5.1.Operating business segments
6.5.2.Business performance
6.5.3.Key strategic moves and developments
6.6.ABCAM PLC
6.6.1.Operating business segments
6.6.2.Business performance
6.6.3.Key strategic moves and developments
6.7.SANTA CRUZ BIOTECHNOLOGY, INC.
6.7.1.Operating business segments
6.7.2.Business performance
6.7.3.Key strategic moves and developments
6.8.HÖLZEL BIOTECH
6.8.1.Operating business segments
6.8.2.Business performance
6.8.3.Key strategic moves and developments
6.9.CHANGZHOU PHARMACEUTICAL FACTORY
6.9.1.Operating business segments
6.9.2.Business performance
6.9.3.Key strategic moves and developments
6.10.ND PHARMA & BIOTECH COMPANY
6.10.1.Operating business segments
6.10.2.Business performance
6.10.3.Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
